Targeting TAK1 to overcome cisplatin resistance in lung adenocarcinoma by rewiring the NF-κB and p53 signaling
- 30 June 2026
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 252, 118206
Abstract
No abstract availableKeywords
Funding Information
- Hainan Provincial Department of Science and Technology
- National Natural Science Foundation of China
This publication has 35 references indexed in Scilit:
- Dendrobin A inhibits gastric cancer: Mechanistic insights supported by integrated evidencePhytomedicine, 2025
- Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBCTranslational Oncology, 2024
- Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivoJournal of Ethnopharmacology, 2022
- Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancerGastric Cancer, 2020
- Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLCLung Cancer, 2019
- TAK -ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapyDrug Resistance Updates, 2017
- Isolation, semisynthesis, covalent docking and transforming growth factor beta-activated kinase 1 (TAK1)-inhibitory activities of (5Z)-7-oxozeaenol analoguesBioorganic & Medicinal Chemistry, 2015
- The IκB kinase complex in NF‐κB regulation and beyondEMBO Reports, 2013
- Shared Principles in NF-κB SignalingCell, 2008
- Mechanisms of resistance to cisplatin and carboplatinCritical Reviews in Oncology/Hematology, 2007